Ptc Therapeutics (PTCT) Capital Expenditures Growth (3y) (2015 - 2026)
Ptc Therapeutics (PTCT) Capital Expenditures Growth (3y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | - |
| 2 | Nanobiotix | 1,913.50 Bn | 1,913.44 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 473.74 Bn | 468.95 Bn | 1.35 Bn | -12.25% |
| 5 | Vertex Pharmaceuticals | 122.07 Bn | 114.82 Bn | 2.59 Bn | 46.88% |
| 6 | Regeneron Pharmaceuticals | 70.00 Bn | 61.24 Bn | 3.31 Bn | 8.97% |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.96 Bn | 50.77 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 16.27% |
| 10 | Ptc Therapeutics | 6.31 Bn | 4.42 Bn | 244.52 Mn | 249.66% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 249.66% |
| Dec 31, 2025 | 34.93% |
| Sep 30, 2025 | -13.82% |
| Jun 30, 2025 | -46.70% |
| Mar 31, 2025 | -43.01% |
| Dec 31, 2024 | -32.10% |
| Sep 30, 2024 | -55.30% |
| Jun 30, 2024 | -43.01% |
| Mar 31, 2024 | 19.14% |
| Dec 31, 2023 | 36.33% |
| Sep 30, 2023 | 24.33% |
| Jun 30, 2023 | 96.89% |
| Mar 31, 2023 | -83.31% |
| Dec 31, 2022 | -90.94% |
| Sep 30, 2022 | 8.16% |
| Jun 30, 2022 | 63.62% |
| Mar 31, 2022 | 48.13% |
| Dec 31, 2021 | 39.80% |
| Sep 30, 2021 | 29.10% |
| Jun 30, 2021 | 124.15% |